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ABSTRACT
Objective: To assess various methods ofmanagement of actinomyces-like organisms associated with
intrauterine devices.
Methods:A retrospective chart review of 173 patients with intrauterine device-associated actino-
myces-like organisms detected on Pap smear was performed. The patients were managed by IUD
removal with or without antibiotic therapy, antibiotic therapy alone, or no treatment at all.
Results: The success rate as reflected in negative follow-up smear was 100% for IUD removal
combined with antibiotics, 97.4% for IUD removal alone, and 36.8% for antibiotics therapy alone.
Conclusions: The best way to manage intrauterine device-associated actinomyces-like organisms
is removal ofthe device with or without antibiotics. (C) 1993 Wiley-Liss, Inc.
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uman actinomycosis was first described by Is-
rael. The first report of genital actinomycosis
infection was made in 1926 in a woman who was
using an intrauterine pessary.
2 Henderson’s
3 re-
port in 1973 brought the association of pelvic acti-
nomycosis and intrauterine contraceptive devices
(IUDs) to the attention ofgynecologists. Since then,
actinomyces colonization has been described in oth-
erwise healthy women without IUDs by Persson
and Holmberg.
4
Gupta and associates
s-7 first described the histo-
morphologic identification of the carriage of acti-
nomyces-like organisms (ALOs) and their associa-
tion with IUDs on Pap smears. Gupta
7 has
demonstrated that Pap-stained cervicovaginal smear
diagnosis ofALOs has both a high specificity (98%)
and sensitivity (94%) when correlated with fluores-
cence antibody staining.
The management ofIUD-associatedALOs iden-
tified on a cervicovaginal Pap smear, especially in
an asymptomatic woman, is difficult, controver-
sial, and without any uniform consensus. It ranges
from leaving the IUD in situ to removal, with or
without reinsertion of a new IUD or antibiotic
treatment.
8-11
Our study assesses some of the ways to manage
ALOs diagnosed by cervicovaginal Pap smears in
asymptomatic IUD users.
MATERIALS AND METHODS
Data were compiled from records of patients at-
tending the Temple University Hospital Family
Planning Clinic from 1975 to 1985. We accumu-
lated a list of 1,745 patients utilizing the IUD as a
means of contraception. These patients’ Pap smear
results were reviewed for the presence of ALOs.
One hundred seventy-three patients were found to
have ALOs on their Pap smears. Pap smears were
the only method used for diagnosis of ALOs. The
patients’ charts were then reviewed to determine the
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date ofIUD insertion and removal and if antibiot-
ics were taken while the IUD was in situ with
presence ofALOs on their Pap smears. Criteria for
inclusion in this study were: 1) Pap smear without
ALOs prior to the insertion of the IUD; 2) Pap
smear positive forALOs after insertion ofthe IUD;
3) follow-up Pap smear within 6 months after treat-
ment; and 4) asymptomatic status at the time of
initial positive Pap smear.
The patients were divided into 4 groups accord-
ing to their management:
Group 1: Removal ofIUD alone
Group 2: Antibiotics alone
Group 3: Removal ofIUD and antibiotics
Group 4: No treatment
It should be noted that removal of the IUD with
or without antibiotics was often carried out for
reasons other than treatment of cervical actinomy-
ces: the presence of abnormal uterine bleeding
(n 27), abnormal uterine bleeding with concom-
itant unrelated infections (n 27), a change to
other forms of contraception (n 31), or the de-
sire for future fertility (n 29). Patients in group
2 received antibiotics for concomitant infections
and not ALOs.
Patients with negative follow-up Pap smears af-
ter treatment were classified as successes, and patients
with persistent ALOs after treatment were deemed
failures. A small number of patients in group 4 with
ALOs were eventually lost to follow-up.
Antibiotics received by patients in groups 2 and
3 were divided into four groups: A) ampicillin,
500 mg 4 times a day for 7-10 days/penicillin, 250
mg 4 times a day for 7-10 days; B) doxycycline, 100
mg twice a day for 7 days/tetracycline, 500 mg 4
times a day for 7 days; C) metronidazole, 250 mg 3
times a day for 7 days; and D) multiple antibiotics
(any combination of the aforementioned antibiotics).
Statistical analyses were performed using Epi
Info (Centers for Disease Control, Atlanta, GA).
The Mantel-Haenszel chi square formula was used.
When a cell value of less than 5 was encountered, a
2-tailed P value was obtained with the Fisher’s
exact test.
RESULTS
There was a total of 173 patients with IUD-associ-
ated ALOs on cervicovaginal Pap smear. Table
TABLE I. Management of IUD-associated ALOs
Follow-up
Type of No. of Negative Positive
Group treatment patients [no. (%)] [no. (%)]
Removal of IUD 76 74 (97.4) 2 (2.6)
2 Antibiotics 38 14 (36.8) 24 (63.2)
3 Antibiotics and 38 38 (100) 0
removal of IUD
4 No treatment 21 3 (14.3) 18 (85.7)
details the results of the management in each of the
four groups described.
Group consisted of 7 6 patients who had ALOs
on the Pap smear. Removal of the IUD alone gave
a success rate of 97.4%. Two patients with persis-
tent ALOs on their post-treatment smears were lost
to follow-up. In group 2 all of the patients who
failed initial antibiotic therapy had their IUDs re-
moved subsequently and had a negative Pap smear
within 2 weeks to 6 months ofIUD removal. Eigh-
teen patients in group 4 who continued to have
positive smears were eventually lost to follow-up.
All patients in this group had a minimum fol-
low-up of 6 months.
The results ofmanagement with removal ofIUD
alone or removal of IUD with antibiotics were
found to be significantly better than management
with antibiotics alone (P 0 and P 0). There
was no difference when removal ofIUD alone was
compared with IUD removal with antibiotics
(P 0.31).
There were 27 patients who had their IUDs
removed because of abnormal uterine bleeding.
Seventeen ofthese patients had IUD removal alone,
while ten patients had IUD removal and antibiot-
ics. All 27 patients had subsequent negative Pap
smears.
The types of antibiotics used in group 2 patients
are presented in Table 2. The ampicillin/penicillin
group was not found to be different from the
doxycycline/tetracycline and metronidazole groups
(P 0.30 and P 0.23). However, patients who
received multiple antibiotics had a better chance of
cure when compared with patients who received
doxycycline/tetracycline (P 0.04).
DISCUSSION
Our retrospective analysis indicates that the best
form of treatment for IUD-associated ALOs is
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TABLE 2. Antibiotic therapy only
Follow-up
No. of Negative Positive
Group patients [no. (%)] [no. (%)]
Ampicillin/penicillin 8 3 (37.5) 5 (62.5)
Doxycycline/tetracycline 12 2 (16.5) 10 (83.3)
Metronidazole 10 4 (40) 6 (60)
Multiple antibiotics 8 5 (62.5) 3 (37.5)
Total 38 14 (36.8) 24 (63.2)
removal of the IUD. Addition of antibiotics at the
time of removal of the IUD does not increase the
overall success rate. Seventy-four of 77 patients
who had only removal of the IUD had subsequent
negative Pap smears, and all 38 patients who had
IUD removal and antibiotics had negative fol-
low-up Pap smears. This difference was not statis-
tically significant (P 0.31).
Treatment with antibiotics without removal of
the IUD gave an overall success rate ofonly 36.8%,
which was significantly less than IUD removal or
IUD removal and antibiotics (P 0). As the pres-
ence of the IUD acts as the focus for this foreign-
body-induced infection, its removal seems essential
for successful therapy.
None ofour patients with IUD-associated ALOs
developed serious upper genital tract infection. This
finding has also been reported by other authors. 4’8’9
However, women with IUD-associated ALOs on
Pap smears of the cervix have been shown to have a
3.6-fold greater incidence ofhospitalization for pel-
vic inflammatory disease (PID).
12 Tubo-ovarian
abscesses have also been reported to be more com-
mon in women with IUDs and colonization of
ALOs when compared with women with IUDs but
not colonized with ALOs.
12 In our study, there
were 27 patients who had their IUDs removed
because of abnormal uterine bleeding. It is proba-
ble that this symptom was secondary to endometri-
tis, but none of these patients had endometrial bi-
opsy for confirmation.
Singh et al.
9 suggested expectant management in
asymptomatic women if IUD-associated ALOs are
noted on Pap smears. This recommendation is based
on their findings of only 4.8% with positive cul-
tures for ALOs in the endometrial biopsies, imply-
ing to them that there is only superficial coloniza-
tion of this organism of the cervix and IUD. This
policy of leaving the device in situ needs further
evaluation. Mao and Guillebaud have suggested
removal and reinsertion of another IUD as satisfac-
tory management of IUD-associated ALOs. In
their study, seven patients who had !UDs removed
for ALOs and a new IUD inserted at the same time
had no evidence of ALOs on subsequent Pap
smears. Spontaneous resolution of IUD-associated
ALOs has also been reported. This occurred in
three of our patients.
Expectant management, as some investigators
have advised, is often an attractive option. Even
though spontaneous resolution does occasionally oc-
cur, it is recommended that patients with IUD-
associated ALOs be managed with removal of the
device. The addition of antibiotics does not signifi-
cantly alter the success rate. These patients should
be followed with repeat Pap smears any time after 2
weeks of treatment. Once a negative smear is ob-
tained, consideration may be given to reinsertion of
a new IUD.
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